Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Receivables (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Receivables for 11 consecutive years, with $502000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables changed N/A year-over-year to $502000.0, compared with a TTM value of $502000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $900000.0, changed N/A over the prior year.
  • Receivables was $502000.0 for Q3 2025 at Lisata Therapeutics, roughly flat from $501000.0 in the prior quarter.
  • Across five years, Receivables topped out at $900000.0 in Q4 2024 and bottomed at $501000.0 in Q2 2025.